Shares on the S&P/ASX 200 Index (ASX: XJO) tumbled on Tuesday, closing the day 1.39% lower thanks to broad based losses across multiple sectors. While the day's trading may have disappointed some investors, there are some companies on the index which are expected to shoot higher this year.
Here are three that I have my eye on. And they're all tipped to rise at least 130% over the next 12 months.

Image source: Getty Images
Catapult Sports Ltd (ASX: CAT)
Catapult is a global sports data and analytics company that provides real-time data to optimise athletes' performance. The tech company reported a 16% revenue uplift in the first half of FY26 and a 19% hike in its annualised contract value (ACV). Catapult expects to maintain strong ACV growth through the second half of FY26, driven by low customer churn and ongoing improvements in margins and cash flow.
Catapult is quickly gaining traction, and its recurring subscriptions means it benefits from customer retention. That translates to a higher and more stable margin.
The ASX 200 company's shares were caught up in broad market sell-off on Tuesday, closing 7% lower for the day at $3.29 a piece. The drop means the shares are now 8% lower for the year. But analysts predict the shares could climb as high as 138% to $7.83 over the next 12 months.
Mesoblast Ltd (ASX: MSB)
Mesoblast is an Australian clinical-stage biotech stock that develops and commercialises allogeneic cellular medicines to treat complex diseases. Some products are already in use, and other cell therapies are in the late stages of clinical trials.
The business has great potential for robust growth this year. Its products are gaining traction and the business is well-funded. The stock has tumbled over the past week but I think this looks like a buying opportunity rather than a reason to panic. If momentum starts to pick up pace the share price can recover its losses quickly.
At the close of the ASX on Tuesday, the ASX 200 biotech shares were down 3% at $2.01. But analysts are bullish that there is good upside ahead. There is a strong buy consensus and a maximum target price of $4.92. That implies a potential 145% upside at the time of writing.
Block Inc (ASX: XYZ)
Block, formerly Square, is a global company best known for providing payment-acquiring and related services to businesses. The company posted some strong profit results late last year but has been caught in a perfect storm of headwinds. These include rising interest rates, regulatory scrutiny, and concerns about buy now, pay later models. The combination slashed investor sentiment towards the end of 2025.
The sell-off has continued into 2026. However, an uptick in investor interest late last week, following the company's results, resulted in a 26% increase in the share price in the past 5 days alone. Analysts think the share price could jump another 186% to $256 over the next 12 months.